Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C1XS
|
||||
| Former ID |
DNC012798
|
||||
| Drug Name |
ZIMELIDINE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Depression [ICD9: 311; ICD10:F30-F39] | Withdrawn from market | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H17BrN2
|
||||
| Canonical SMILES |
CN(C)CC=C(C1=CC=C(C=C1)Br)C2=CN=CC=C2
|
||||
| InChI |
1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9+
|
||||
| InChIKey |
OYPPVKRFBIWMSX-CXUHLZMHSA-N
|
||||
| CAS Number |
CAS 56775-88-3
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent serotonin transporter | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Serotonergic synapse | ||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| WikiPathways | Monoamine Transport | ||||
| SIDS Susceptibility Pathways | |||||
| NRF2 pathway | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| REF 1 | The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol. 1986;9(1):46-51. | ||||
| REF 2 | Pharmacokinetic study of zimelidine using a new GLC method. Clin Pharmacokinet. 1983 Nov-Dec;8(6):530-40. | ||||
| REF 3 | J Med Chem. 1984 Nov;27(11):1508-15.Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.